Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,152 matching trials from the live ClinicalTrials.gov search.
Filters: "cardiomyopathy" Clear all
Active, not recruiting No phase listed Observational

A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's

NCT06290570
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
12-Lead ECG, Apple Smart Watch Single Lead ECG, AliveCor KardiaMobile 6-Lead ECG
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Vitamin D3 Supplementation for Heart Failure Patients

NCT01636570
View directory record Official record
Conditions
Heart Failure, Vitamin D Deficiency, Cardiomyopathy, Congestive Heart Failure
Interventions
Placebo Comparator: Sugar Pill, Vitamin D3 (cholecalciferol)
Drug
Lead sponsor
Heidi Moretti, MS, RD
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

NCT00447694
View directory record Official record
Conditions
Beta-thalassemia, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis
Industry
Eligibility
10 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 4, 2026, 5:03 PM EDT
Not listed Not applicable Interventional Results available

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS

NCT01626079
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Valve Regurgitation, Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects, Heart Failure
Interventions
MitraClip System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 4, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

NCT06551129
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 4, 2026, 5:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

NCT03934905
View directory record Official record
Conditions
Anthracycline Related Cardiotoxicity in Breast Cancer
Interventions
sulforaphane, Placebo Oral Tablet
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy

NCT05713916
View directory record Official record
Conditions
Hypertrophy, Left Ventricular, Hypertension, Cardiomyopathies
Interventions
Intervention: Population Health Coordinator
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 75 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 4, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

NCT07690436
View directory record Official record
Conditions
Transthyretin Amyloid Cardiomyopathy
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Palo Alto, California • Jacksonville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

A Post-Market Assessment of the Safety and Performance of the TriClip™ System

NCT07586995
View directory record Official record
Conditions
Tricuspid Regurgitation (TR)
Interventions
Tricuspid Transcatheter Edge-to-Edge Repair (TEER)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
La Jolla, California • Chicago, Illinois • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Early Phase 1 Interventional Results available

Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure

NCT00657280
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Sitagliptin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 4, 2026, 5:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

NCT02316314
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Cardiac magnetic resonance imaging (CMR), Exercise-stress test, Echocardiogram (ECHO), Cardiac-related blood studies
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD

NCT02013375
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Haploidentical Transplant, Alemtuzumab, Total Body Irradiation, Cyclophosphamide, Sirolimus
Procedure · Drug · Radiation
Lead sponsor
Damiano Rondelli, MD
Other
Eligibility
16 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

NCT04847557
View directory record Official record
Conditions
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Huntsville, Alabama • Beverly Hills, California • Covina, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

NCT04737265
View directory record Official record
Conditions
Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma, Cardiomyopathies, Heart Failure
Interventions
Biomarker Guided Intervention
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811
View directory record Official record
Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions
NNC6019-0001, Placebo (NNC6019-0001)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
63
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation

NCT07008911
View directory record Official record
Conditions
Aortic Valve Stenosis, Aortic Valve Disease
Interventions
CardioHeartConnect, CardioHeartEd
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen

NCT02721511
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Furosemide Injection Solution 8mg/mL
Drug
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional Results available

Adjusting to Chronic Conditions Using Education, Support, and Skills

NCT01149772
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Heart Failure, Anxiety, Depression
Interventions
ACCESS
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 4, 2026, 5:03 PM EDT
Completed No phase listed Observational

Observational Hemodynamic Monitoring During LVAD Implantation Among Individuals With Advanced Heart Failure

NCT03464981
View directory record Official record
Conditions
Heart Failure, Circulatory Disorders Postprocedural Complication, Cardiomyopathy, Congestive, Surgery
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 4, 2026, 5:03 PM EDT
Completed No phase listed Observational

CRM and Fusion Beats: Effects of Progressive Fusion on Intra-left Ventricular Mechanical Function

NCT00610896
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Not listed
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 4, 2026, 5:03 PM EDT
Active, not recruiting Phase 4 Interventional

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

NCT06260059
View directory record Official record
Conditions
Adult Congenital Heart Disease, Heart Failure
Interventions
Empagliflozin 10 MG, Placebo
Drug
Lead sponsor
Anita Saraf
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

NCT06608823
View directory record Official record
Conditions
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Interventions
Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System, SAVR
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
Not listed
Enrollment
1,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
34
States / cities
Burlingame, California • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 5:03 PM EDT
Completed No phase listed Observational

Investigation in Pregnancy Associate Cardiomyopathy

NCT01085955
View directory record Official record
Conditions
Cardiomyopathy, Pregnancy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
28
States / cities
Los Angeles, California • Miami, Florida • Augusta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818
View directory record Official record
Conditions
Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Genetic · Procedure
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
22
States / cities
San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 4, 2026, 5:03 PM EDT